The following is a list of the top ten pharmaceutical stocks for 2017.1.
Tylenol PharmaceuticalsTylenols (NASDAQ:TREN)Tylenoals is a generic version of Tylenic, a pain reliever.
Its a relatively inexpensive pain reliever and it’s often used by people who have chronic pain.
The company has been a leader in the market, so there is little reason why the stock shouldn’t improve over the next year.
There is a good chance that Tylenoal could grow in price in the near term.
The stock is currently trading at around $14 per share.2.
Merck & Co (NASdaq:MRK)The Merck Company (NYSE:M&K)is a biopharmaceutical company that manufactures and sells generic versions of generic medicines.
The drugmaker has been very aggressive in its price increase, making it one of the most valuable stocks on the list.
There are a lot of good generic options out there, but Merck has had some good years recently.
The average price of a generic of Merck’s stock was $14.25 in 2017.3.
Valeant PharmaceuticalsValeant Pharmaceutical is an Australian-based pharmaceutical company that makes generic versions and pharmaceuticals for other pharmaceutical companies.
The drugs are generally cheaper and have higher effectiveness than brand-name versions.
Valeants shares are currently trading around $21.60 per share, which is a little over $5 per share above the $15.00 per share average that we listed earlier.4.
Novartis (NYSE)Novartis is a biotechnology company that develops and manufactures a wide range of drugs and vaccines for a wide variety of diseases.
It was founded in the late 1800s and has grown into a large company that is one of America’s largest drug companies.
Novarts shares have risen over the last year and are currently at $28.75 per share on average.5.
Eli Lilly &.
(NYSE :LLY)A generic of EpiPen (NYSE -EP), Eli Lilly’s generic version was one of its first and most successful drugs.
The generic version is used by millions of people worldwide.
There have been a lot better generic versions on the market in the last several years.
Eli has had a great year recently, rising by over $1,000 per share in 2017 alone.6.
Pfizer (NYSE )Pfizer is an American pharmaceutical company founded in 1889.
It has grown rapidly over the years, becoming the second-largest drug company in the world.
Pfizers shares are up around $1.70 per share since it was founded.7.
Allergan (NAS)Allergan is a global health care company that specializes in treating infections and diseases such as pneumonia, malaria, and asthma.
It recently raised $4 billion in venture capital funding.
Allergies to the drugs are one of Allergen’s biggest growth areas.
Allergy treatments can be expensive and can be difficult to find.
Allerdigens shares have increased in the past few years, rising between $4.90 and $5.90 per share for the past several years and are now at a high of $10.25 per share today.8.
Gilead SciencesGilead is a biotech company that sells a wide array of treatments for various diseases and diseases that affect people’s health.
The prices for Gileads drugs are relatively high, so its easy to overlook.
Its one of a few companies that have a lot going for them, and its one of several companies that can be found in the top five in the U.S. stock market.
Gifers shares are on track to rise in price over the coming year, rising from $11.50 to $13.50 per share by the end of 2018.9.
Johnson &.; Johnson (NYSE): Johnson & Johnson is a British-based drugmaker.
Its also a biomedicine company.
Its most popular product is the Lipitor, which treats certain types of cancer.
The Lipitor is a long-acting treatment that can work for years and prevent the spread of certain types to patients.
Its an expensive product, but its one that people want and can afford.
G& has been one of Johnson &s top performers recently.
Its currently trading between $15 and $17 per share and the stock is expected to continue to rise.10.
Pfist AGPfist is a German-based biotechnology giant that develops, manufactures, and sells pharmaceuticals and biological products.
Its the biggest player in the bioscience market.
Pfists stock is on track for a strong year, up between $2.90 to $3.00 over the past two years.